Who are 15-valent pneumococcal conjugate vaccine (PCV15)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Prevnar 20, Prevnar family, PCV13 alone, PPV Vaccine, Prevenar 20, Ppsv23.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/15-valent-pneumococcal-conjugate-vaccine-pcv15.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

15-valent pneumococcal conjugate vaccine (PCV15) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

15-valent pneumococcal conjugate vaccine (PCV15) (15-valent-pneumococcal-conjugate-vaccine-pcv15) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: vaccine. Area: Immunology.

marketed vaccine Streptococcus pneumoniae Immunology Vaccine Live · refreshed every 30 min

Target snapshot

15-valent pneumococcal conjugate vaccine (PCV15) (15-valent-pneumococcal-conjugate-vaccine-pcv15) — Pfizer.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
15-valent pneumococcal conjugate vaccine (PCV15) TARGET	15-valent-pneumococcal-conjugate-vaccine-pcv15	Pfizer	marketed	vaccine	Streptococcus pneumoniae
Prevnar 20	pneumococcal 20-valent conjugate vaccine (PCV20)	Pfizer Inc.	marketed	Pneumococcal conjugate vaccine	Streptococcus pneumoniae capsular polysaccharides (20 serotypes)	2021-06-08
Prevnar family	prevnar-family	Pfizer Inc.	marketed	Vaccine	Streptococcus pneumoniae
PCV13 alone	PCV13 alone	Korea University Guro Hospital	marketed	Pneumococcal conjugate vaccine	Streptococcus pneumoniae polysaccharide capsule (13 serotypes)
PPV Vaccine	PPV Vaccine	Fakultas Kedokteran Universitas Indonesia	marketed	Polysaccharide vaccine	Streptococcus pneumoniae capsular polysaccharides
Prevenar 20	prevenar-20	Pfizer	marketed	Vaccine	Streptococcus pneumoniae
Ppsv23	ppsv23	Pfizer	marketed	Vaccine	Streptococcus pneumoniae

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2033-06-01 — Prevnar 20 · US 8,895,024 · Composition of matter · US
2035-06-01 — Prevnar 20 · US 10,279,033 · Method of use · US

Sponsor landscape (vaccine class)

Pfizer · 20 drugs in this class
Sanofi Pasteur, a Sanofi Company · 20 drugs in this class
GlaxoSmithKline · 12 drugs in this class
Merck Sharp & Dohme LLC · 12 drugs in this class
Centers for Disease Control and Prevention · 9 drugs in this class
Zhejiang Provincial Center for Disease Control and Prevention · 7 drugs in this class
Jiangsu Province Centers for Disease Control and Prevention · 6 drugs in this class
Beijing Center for Disease Control and Prevention · 6 drugs in this class
International Centre for Diarrhoeal Disease Research, Bangladesh · 5 drugs in this class
Sinovac Biotech Co., Ltd · 4 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). 15-valent pneumococcal conjugate vaccine (PCV15) — Competitive Intelligence Brief. https://druglandscape.com/ci/15-valent-pneumococcal-conjugate-vaccine-pcv15. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab